Physician profile
Yale M Samole
NPI 1477515161
$3,671.43
in general payments reported to CMS, 2019-2025
33 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $157 · 2021: $197 · 2022: $507 · 2023: $269 · 2024: $674 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $558.07 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $449.35 | 2019-2025 | |
| Abbott Laboratories | $262.97 | 2021-2024 | Navitor |
| Novartis Pharmaceuticals Corporation | $206.92 | 2021-2025 | |
| Boston Scientific Corporation | $174.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $173.79 | 2019-2023 | |
| Medtronic Vascular, INC. | $168.28 | 2019 | |
| Amarin Pharma, INC. | $160.03 | 2019-2020 | |
| Gilead Sciences, INC. | $132.38 | 2019 | |
| Astellas Pharma US INC | $131.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.49 | 2020-2025 | Farxiga, Wainua |
| Alnylam Pharmaceuticals INC. | $129.69 | 2023-2024 | Onpattro |
| Amgen INC. | $122.32 | 2019-2025 | Repatha |
| Heartflow, INC. | $118.45 | 2024 | |
| Novo Nordisk INC | $117.03 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $79.69 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $76.74 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $55.11 | 2024-2025 | Optimizer |
| Atricure, INC. | $53.99 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $49.81 | 2021-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $36.32 | 2024-2025 | Verquvo |
| Esperion Therapeutics, INC. | $36.20 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.00 | 2022-2023 | |
| Novocure INC. | $30.18 | 2025 | Optune Lua (Novottf-200t) |
| Bridgebio Pharma, INC. | $29.98 | 2025 | Attruby |
| Medtronic, INC. | $21.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2024 | Jardiance |
| Lilly USA, LLC | $17.66 | 2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $16.55 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.19 | 2019 | |
| Akcea Therapeutics, INC. | $14.72 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yale Samole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.